NASDAQ: ARTL - Artelo Biosciences, Inc.

Yield per half year: -16.09%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Artelo Biosciences, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.

more details
12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2017-11-14
ISIN US04301G5080
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.artelobio.com
Цена ао 0.971
Change price per day: -2.59% (0.965)
Change price per week: -9.62% (1.04)
Change price per month: -13.67% (1.0889)
Change price per 3 month: -11.32% (1.06)
Change price per half year: -16.09% (1.1202)
Change price per year: -36.49% (1.48)
Change price per 3 year: +115.79% (0.4356)
Change price per 5 year: -12.15% (1.07)
Change price per year to date: -2.08% (0.96)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 1.2 9
P/E 0 0
EV/EBITDA 0.1513 10
Total: 4.88

Efficiency

Title Value Grade
ROA, % -110.77 0
ROE, % -134.52 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0061 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 145.24 10
Yield EPS, % -83.62 0
Total: 5.8
More

Institutions Volume Share, %
Geode Capital Management, LLC 19808 0.61
Tower Research Capital LLC (TRC) 4803 0.15
Wells Fargo & Company 22 0
Morgan Stanley 20 0
Osaic Holdings Inc 7 0
NewEdge Advisors, LLC 1 0



Head Job title Payment Year of birth
Mr. Gregory D. Gorgas M.B.A. President, CEO, CFO, Treasurer, Secretary & Director 742.45k 1963 (62 years)
Dr. Andrew Yates Ph.D. Senior VP & Chief Scientific Officer N/A
Dr. Steven D. Reich Chief Medical Officer N/A 1946 (79 years)
Mr. Jason H. Baybutt Senior Vice President of Finance N/A 1972 (53 years)

Address: United States, Solana Beach. CA, 505 Lomas Santa Fe - open in Google maps, open in Yandex maps
Website: https://www.artelobio.com